About
Lars Sandberg serves as a Visiting Researcher in the Department of Medicinal Chemistry at Uppsala University, Sweden, specifically affiliated with the Preparative Medicinal Chemistry division at the Uppsala Biomedicinska Centrum (BMC). His work centers on pharmaceutical compound development within the university's biomedical research framework.
His research specializes in enzyme-targeted drug design, with particular emphasis on dihydroorotate dehydrogenase inhibition and metabolic stability profiling. Key interests include optimizing heterocyclic compounds like tetrahydroindazoles for enhanced pharmacological properties, balancing biological activity with metabolic resistance through structural modifications.
His 2020 publication demonstrates significant engagement in contemporary medicinal chemistry challenges, specifically addressing the dual requirements of target inhibition potency and metabolic durability in drug candidates. This work reflects current trends in rational drug design where computational and experimental approaches converge to solve pharmacokinetic limitations.
